Harbour BioMed (HKEX: 02142), a Hong Kong-based global biopharmaceutical company, announced on Sunday that it has dosed the first patient in its ongoing phase I trial of the first-in-class anti-B7H7 (HHLA2) antibody HBM1020 (NCT05824663/Study 1020.1) in the United States.

The study is assessing the safety, tolerability, pharmacokinetics, and anti-tumour activity of HBM1020 in subjects with advanced solid tumours. HBM1020 is generated from the Harbour Mice H2L2 transgenic mice platform and is claimed to be the first therapeutic monoclonal antibody against B7H7/HHLA2 entering clinical development worldwide.

Dr Jingsong Wang, Harbour BioMed founder, chairman and CEO, said, 'We are delighted to announce the dosing of the first patient with our first-in-class B7H7/HHLA2 antibody HBM1020. This milestone is a significant accomplishment for our team and represents a major step forward in our mission to transform patient care. We are excited about the potential of the B7H7/HHLA2 antibody to make a meaningful difference in the lives of patients suffering from advanced malignancies and we remain dedicated to advancing its clinical development globally.'